ESPE2014 Poster Category 2 Puberty and Neuroendocrinology (1) (12 abstracts)
Evaluation of Age at GnRH Analogue Treatment Discontinuation, Age at Menarche and Adult Height in Girls with Central Precocious Puberty from the Spanish Registry
Raquel Corripio a , Leandro Soriano-Guillén b , Ramón Cañete c , Lidia Castro-Feijoó d , Arancha Escribano e , Rafael Espino f , Javier Herrero-Espinet g , José-Ignacio Labarta h & Jesús Argente i
aHospital Sabadell, Corporació Parc Taulí, UAB, Sabadell, Barcelone, Spain; bHospital Fundación Jiménez Díaz, Madrid, Spain; cHospital Universitario Reina Sofía, Córdoba, Spain; dHospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain; eHospital Universitario Virgen de la Arrixaca, Murcia, Spain; fH. Universitario Virgen de Valme, Sevilla, Spain; gHospital St. Jaume de Calella, Barcelone, Spain; hHospital Miguel Servet, Zaragoza, Spain; iHospital Universitario Niño Jesús, Madrid, Spain
Background: The Spanish Registry PUBERE was created (2007) with 53 hospitals.
Objective and hypotheses: i) To determine the chronological age (CA) and bone (BA) at GnRH analogue withdrawal; ii) to analyze the age at menarche and time elapsed after stopping treatment; and iii) to know adult height data.
Method: Patients with central precocious puberty (CPP) born after 1992, diagnosed before 8 years in girls, with BA/CA >1 year and LH peak after LHRH >7 IU/l, were included. At diagnosis we calculated the adult height (AH) prediction (Bayley and Pineau method) in cm and SDS according to the reference population. We also collected data of GnRH analogue withdrawal (BA and CA), age at menarche and AH data (cm and SDS).
Results: 386 patients (19.9% adopted and 87.4% idiopathic) were included. The CA at treatment onset was 7.26±1.31 years and the BA 9.10±1.51 years. The average CA at treatment discontinuation was 10.15±1.01 years (n=186), coinciding with a BA of 11.6±0.67 years. The age at menarche was 11.04±1.14 years (n=106), occurring 13.52±7.14 months after stopping treatment. The mean increase in height after treatment discontinuation was 13.1±4.3 cm. Mean AH (n=30) was 157.5±11.03 cm (SDS: −0.66±1.98). The mean PAH at diagnosis was 161.5±10.9 cm, so the mean difference between AH and PAH at diagnosis was −3.76±8.61 cm (95% CI: −6.98 to −0.55 cm; P=0.023).
Conclusion: i) The AH of PPC patients was significantly lower than their PAH, but within the margin of error of this method (95% CI: ±6 cm). ii) Treatment withdrawal was done before the age of pubertal onset average in our population. iii) Menarche occured about 13 months after stopping treatment.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more